Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162-170.
Margalit O, Harmsen WS, Shacham-Shmueli E, Voss MM, Boursi B, Wagner AD, Cohen R, Olswold CL, Saltz LB, Goldstein DA, Hurwitz H, Tebbutt NC, Kabbinavar FF, Adams RA, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, de Gramont A, Shi Q, Lenz HJ. Margalit O, et al. Among authors: goldstein da. Eur J Cancer. 2023 Nov;194:113339. doi: 10.1016/j.ejca.2023.113339. Epub 2023 Sep 28. Eur J Cancer. 2023. PMID: 37813779 No abstract available.
Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.
Margalit O, Harmsen WS, Shacham-Shmueli E, Voss MM, Boursi B, Wagner AD, Cohen R, Olswold CL, Saltz LB, Goldstein DA, Hurwitz H, Tebbutt NC, Kabbinavar FF, Adams RA, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, de Gramont A, Shi Q, Lenz HJ. Margalit O, et al. Among authors: goldstein da. Eur J Cancer. 2023 Jan;178:162-170. doi: 10.1016/j.ejca.2022.10.022. Epub 2022 Nov 2. Eur J Cancer. 2023. PMID: 36446161 Free article.
The tyranny of non-inferiority trials.
Tannock IF, Buyse M, De Backer M, Earl H, Goldstein DA, Ratain MJ, Saltz LB, Sonke GS, Strohbehn GW. Tannock IF, et al. Among authors: goldstein da. Lancet Oncol. 2024 Oct;25(10):e520-e525. doi: 10.1016/S1470-2045(24)00218-3. Lancet Oncol. 2024. PMID: 39362263 Review.
Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.
Tannock IF, Bouche G, Goldstein DA, Goto Y, Lichter AS, Prabhash K, Ranganathan P, Saltz LB, Sonke GS, Strohbehn GW, von Moos R, Ratain MJ. Tannock IF, et al. Among authors: goldstein da. Ann Oncol. 2023 Aug;34(8):638-644. doi: 10.1016/j.annonc.2023.05.006. Epub 2023 May 23. Ann Oncol. 2023. PMID: 37230253 Free article. No abstract available.
Non-inferiority trials: tyranny or good governance? - Authors' reply.
Tannock IF, Buyse M, De Backer M, Earl H, Goldstein DA, Ratain MJ, Saltz LB, Sonke GS, Strohbehn GW. Tannock IF, et al. Among authors: goldstein da. Lancet Oncol. 2025 Jan;26(1):e8. doi: 10.1016/S1470-2045(24)00717-4. Lancet Oncol. 2025. PMID: 39756458 No abstract available.
Validation of the Online Collaborative Ocular Tuberculosis Study Calculator for Tubercular Uveitis.
Zhang L, Rojas-Carabali W, Choo SS, Thng ZX, Lim YH, Lee B, Jun SW, Patnaik G, Biswas J, Agarwal A, Testi I, Mahajan S, Kempen JH, Smith JR, McCluskey P, Kon OM, Nguyen QD, Pavesio C, Gupta V, Agrawal R; Collaborative Ocular Tuberculosis Study (COTS) Group. Zhang L, et al. JAMA Ophthalmol. 2024 Dec 1;142(12):1140-1148. doi: 10.1001/jamaophthalmol.2024.4567. JAMA Ophthalmol. 2024. PMID: 39480402
Use of immunomodulatory treatment for non-infectious uveitis: an International Ocular Inflammation Society report of real-world practice.
Branford JA, Bodaghi B, Ferreira LB, McCluskey PJ, Thorne JE, Matthews JM; International Study Group for Systemic Immunomodulatory Drug Treatment of Non‐Infectious Uveitis; Smith JR. Branford JA, et al. Br J Ophthalmol. 2024 Nov 1:bjo-2024-326239. doi: 10.1136/bjo-2024-326239. Online ahead of print. Br J Ophthalmol. 2024. PMID: 39472042
451 results